Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Pembrolizumab + pTVG-AR + pTVG-HP plasmid DNA vaccine + Sargramostim|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Pembrolizumab||Keytruda||MK-3475||Immune Checkpoint Inhibitor 135 PD-L1/PD-1 antibody 80||Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous squamous cell carcinoma, MSI-H or dMMR or TMB high advanced solid tumors, CD274 (PD-L1)-expressing NSCLC, gastric and GEJ adenocarcinoma, squamous esophageal carcinoma, cervical cancer, and triple-negative breast cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib or lenvatinib in RCC, with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemotherapy for patients with esophageal or gastroesophageal carcinoma, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma, and in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-expressing (CPS>=1) cervical cancer (FDA.gov).|
|pTVG-AR||MVI-118||pTVG-AR (MVI-118) is a DNA vaccine encoding the ligand binding domain of the androgen receptor (AR) that stimulates immune response against AR-expressiong prostate cancer cells (PMID: 23108626, PMID: 32513836).|
|pTVG-HP plasmid DNA vaccine||pTVG-HP plasmid DNA vaccine contains human prostatic acid phosphatase (PAP)-encoding plasmid DNA, which induces cytotoxic immune response towards tumor cells expressing PAP (PMID: 17102977).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04090528||Phase II||Pembrolizumab + pTVG-AR + pTVG-HP plasmid DNA vaccine + Sargramostim Pembrolizumab + pTVG-HP plasmid DNA vaccine + Sargramostim||pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer||Recruiting||USA||0|